BioTuesdays

Tag - H.C. Wainwright

XOMA
Markets

HCW ups XOMA PT to $56 from $30

H.C. Wainwright raised its price target for XOMA (NASDAQ:XOMA) to $56 from $30, citing the company’s growing asset base, which is linked to both increasing levels of milestone payments and future royalty potential from...

January 19, 2021
Kazia
Markets

HCW starts Kazia Therapeutics at buy; PT $17

H.C. Wainwright launched coverage of Kazia Therapeutics (NASDAQ:KZIA) with a “buy” rating and price target of $17. The stock closed at $8.98 on Jan. 4. Kazia is developing novel therapies against brain cancer. Its lead...

January 5, 2021
Alpine Immune Sciences
Markets

HCW starts Alpine Immune Sciences at buy; PT $21

H.C. Wainwright launched coverage of Alpine Immune Sciences (NASDAQ:ALPN) with a “buy” rating and $21 price target. The stock finished at $14.57 on Dec. 18. Alpine is leading the way in developing protein-based...

December 21, 2020
Arbutus Biopharma Logo
Markets

HCW starts Arbutus Biopharma at buy; PT $10

H.C. Wainwright launched coverage of Arbutus Biopharma (NASDAQ:ABUS) with a “buy” rating and price target of $10. The stock closed at $4.41 on Dec. 16. Arbutus is primarily focused on discovering, developing and...

December 17, 2020
Curis Logo
Markets

HCW ups Curis PT to $9 from $5

H.C. Wainwright raised its price target for Curis (NASDAQ:CRIS) to $9 from $5 after the company announced preliminary data from an ongoing Phase 1 study evaluating monotherapy, CA-4948, in relapsed or refractory acute...

December 8, 2020
Prothena
Markets

HCW starts Prothena at buy; PT $22

H.C. Wainwright launched coverage of Prothena (NASDAQ:PRTA) with a “buy” rating and price target of $22. The stock closed at $11.53 on Dec 4. Prothena is focused on protein-opathies affecting the central nervous system...

December 7, 2020
Markets

HCW starts BiomX at buy; PT $20

H.C. Wainwright initiated coverage of BiomX (NYSE American:PHGE) with a “buy” rating and $20 price target. The stock closed at $5.90 on Dec 4. “BiomX is one of the leaders in the development of bacteriophage (phage)...

December 7, 2020
Liquidia Logo
Markets

HCW starts Liquidia Technologies at buy; PT $6

H.C. Wainwright initiated coverage of Liquidia Technologies (NASDAQ:LQDA) with a “buy” rating and price target of $6. The stock closed at $2.92 on Dec. 3. Liquidia is focused on applying its particle engineering PRINT...

December 4, 2020
Curis Logo
Markets

HCW starts Curis at buy; PT $5

H.C. Wainwright initiated coverage of Curis (NASDAQ:CRIS) with a “buy” rating and price target of $5. The stock closed at $1.35 on Nov. 23. Curis is developing two novel therapeutics for three potential indications that...

November 24, 2020

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.